ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge
Massachusetts
02139
United States
Tel: 617-494-0400
Fax: 617-225-2860
Website: http://www.ariad.com/
About ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
526 articles about ARIAD Pharmaceuticals, Inc.
-
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
-
Pharma giant Takeda Pharmaceutical is looking to begin 2019 with a bang – closing its $62 billion acquisition of Shire plc by Jan. 8. This morning Takeda announced that it will hold an investor vote next month on the planned acquisition in order to swiftly move and finalize the deal.
-
One day after it was revealed Takeda is moving its U.S. headquarters from Illinois to Boston ahead of the completion of the Shire Plc acquisition, the Japanese company is reportedly considering the sale of Shire’s eye-care business in order to cut some debt incurred from funding the $62 billion d...
-
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve
7/25/2018
Takeda Pharmaceutical Company Limited today announced that the global, randomized, Phase 3 ALTA-1L trial met its primary endpoint at the first pre-specified interim analysis, with ALUNBRIG®.
-
UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion
4/24/2018
Takeda Pharmaceutical has come back with an improved bid for Shire, making it the fifth round of talks. -
Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan...
-
Announcing a Proposed Class Action Settlement Involving All Persons that Purchased Shares of ARIAD Pharma Publicly Traded Common Stock During Settlement Class Period
2/12/2018
To participate in the Settlement, you must submit a Claim Form online using the settlement website .
-
It's Official: Shire Takes Over Ariad's Old Space in Kendall Square
10/10/2017
-
Jounce Names Ex-Ariad's Top Dealmaker as Its New CBO
8/16/2017
-
Two Former Ariad Directors Charged With Insider Trading
6/29/2017
-
Takeda's $5 Billion Bet on Ariad Pays Off With Accelerated Approval of Lung Cancer Med
5/1/2017
-
Why Ex-Ariad CEO Joining This Biotech's Board Could Mean a Buyout Deal Is Coming
4/7/2017
-
Mass Layoffs Hit Ariad Employees After Takeda's $5.2 Billion Buyout Deal
3/31/2017
-
Takeda Completes Acquisition Of Ariad
2/17/2017
-
First Ariad, Now Senator Bernie Sanders Puts This Drug Company on Notice
2/16/2017
-
Ariad Announces Submission Of Marketing Authorization Application For Brigatinib To EMA
2/6/2017
-
Ariad Stays Mum on Layoffs After Takeda's $5.2 Billion Takeover
1/30/2017
-
A Peek Behind the Curtain of the Ariad-Takeda Deal
1/20/2017
-
After Ariad, These 3 Drug Cancer Firms Could be Taken Out Next
1/12/2017
-
Takeda Swallows Up Struggling Ariad in $5.2 Billion Deal
1/10/2017